Related Experiment Video
Updated: May 17, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
934
Refractory pediatric actinic prurigo successfully treated with upadacitinib: A case report
Florence Morissette1, Jérome Coulombe2
1Dermatology Division, Department of Medicine, CHUM, University of Montreal, QC, Canada.
SAGE Open Medical Case Reports
|May 15, 2025
Abstract:
Actinic prurigo is a rare photodermatosis, usually occurring during childhood. Pruritic papulonodules on sun-exposed areas are frequently associated with cheilitis and conjunctivitis. The most widely accepted pathophysiology to date is a type IV hypersensitivity reaction triggered by ultraviolet radiation. This case report describes a 12-year-old boy suffering from refractory actinic prurigo, who was successfully treated with the janus kinase inhibitor upadacitinib.

